9345/01.10.21

File No. FDC/MA/20/000150

Tele. No. : 011-23236965
Fax No. : 011-23236973

Govt. of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(FDC Division)

FDA Bhawan, Kotla Road
New Delhi-110002
Dated:

15 NOV 2021

To,
M/s. Kusum Healthcare Pvt. Ltd.,
Plot No. M-3, Indore Special Economic Zone,
Phase- II, Pithampur, Dist-Dhar
Madhya Pradesh–454774.

Subject: Permission to conduct Phase IV clinical trial with the FDC of Zinc Citrate Trihydrate eq. to Zinc IP 10mg + Ascorbic Acid IP 1000mg effervescent tablets (Vide protocol no. CRS/21/001, Version no. 01, Amendment no. 01, dated: 13.07.2021)-regarding.

Dear Sir,

With reference to your online application submitted in Form CT-21 on dated 19.10.2020 please find enclosed herewith the "permission to conduct clinical trial study of new drug" bearing no. **CT-06-184/2021** under the provision of Drugs and Cosmetics Act and Rules. The permission is subject to the conditions mentioned below.

Kindly acknowledge receipt to this letter and its enclosures.

Yours faithfully,

(Dr. V. G. Somani)
Drugs Controller General (India)

CONDITIONS OF PERMISSION

I. Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

II. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
   i. Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
   ii. Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

III. In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

IV. The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

Permission no.: CT-06-184/2021

1. The Central Licencing Authority hereby permits **M/s. Kusum Healthcare Pvt. Ltd., Plot No. M-3, Indore Special Economic Zone, Phase- II, Pithampur, Dist-Dhar Madhya Pradesh–454774.** (Name and full address with contact details of the applicant) to conduct clinical trial of the new drug or investigational new drug as per protocol number **(Vide protocol no. CRS/21/001, Version no. 01, Amendment no. 01, dated: 13.07.2021)** in the below mentioned clinical trial sites.
2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date: 15 NOV 2021

Central Licencing Authority

Stamp
Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug:	Zinc Citrate Trihydrate eq. to Zinc IP 10mg + Ascorbic Acid IP 1000mg effervescent tablets
Therapeutic class:	Dietary supplement of Vitamin C and Zinc
Dosage form:	Effervescent Tablets
Composition:	Zinc Citrate Trihydrate eq. to Zinc IP 10mg + Ascorbic Acid IP 1000mg effervescent tablets
Indications:	It is used for the treatment of Vitamin C and Zinc deficiencies.

Details of clinical trial site:

Names and address of clinical trial site:	As per annexure- A
Ethics committee details:	As per annexure- A
Name of principal investigator:	As per annexure- A

Annexure-A

Permission no.: CT-06-184/2021

S. No.	Name of PI	Site Name	Ethics Committee Name, Address & EC registration No
1	Dr. Nirhali Sonali Chandrakant	Lifepoint Multispecialty Hospital, Pune, 145/1, Mumbai Bangalore Highway, Near Hotel Sayaji, Wakad, Pune, Maharashtra 411057.	LPR Ethics Committee, 145/1, Mumbai Bangalore Highway, Near Hotel Sayaji, Wakad, Pune, Maharashtra 411057 ECR/751/Inst/MH/2015/RR-21
2	Dr. K. Sunil Naik	Department of General Medicine, Government Medical College & Govt General Hospital (Old RIMSGGH), Srikakulam – 532001, Andhra Pradesh, India	Institutional Ethics Committee, Govt. Medical College Govt. General Hospital, Srikakulam Andhra Pradesh, India ECR/492/Inst/AP/2013/ RR-20
3	Dr. Richa Giri	Post Graduate Department of Medicine, GSVM Medical College, Swaroop Nagar, Kanpur, Uttar Pradesh-208002	Ethics Committee, G.S.V.M Medical College, Room no. 125, 1st Floor, Swaroop Nagar, Kanpur-208002, Uttar Pradesh. ECR/680/Inst/UP/2014/RR-20
4	Dr. Arindam Naskar	School of Tropical Medicine, 108, Chitaranjan Avenue, Kolkata-700073, West Bengal, India	Clinical Research Ethics Committee School of Tropical Medicine, 108, Chittaranjan Avenue, Kolkata-700073, West Bengal, India ECR/194/Inst/WB/2013/RR-20
5	Dr. Sujata Devi	Department of General Medicine, AIIMS Bhubaneshwar, Sijua, Patrapada, PO-Dumduma, Odisha, India-751019.	Institutional Ethics Committee, AIIMS Bhubaneshwar, Sijua, Patrapada, PO-Dumduma, Odisha India-751019. ECR/534/Inst/OD/2014/RR-20

Place: New Delhi

Date: .....

15 NOV 2021

Central Licencing Authority

Stamp

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002